Seven Fleet Capital Management LP Sells 96,652 Shares of Silence Therapeutics PLC Sponsored ADR $SLN

Seven Fleet Capital Management LP decreased its holdings in Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) by 61.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 60,107 shares of the company’s stock after selling 96,652 shares during the quarter. Seven Fleet Capital Management LP’s holdings in Silence Therapeutics were worth $660,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Silence Therapeutics by 18.1% in the second quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after acquiring an additional 1,698 shares during the period. Boothbay Fund Management LLC boosted its stake in shares of Silence Therapeutics by 1.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock worth $1,464,000 after acquiring an additional 2,409 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Silence Therapeutics by 6.6% during the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after acquiring an additional 3,935 shares during the period. ADAR1 Capital Management LLC increased its stake in shares of Silence Therapeutics by 26.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in shares of Silence Therapeutics by 4.4% in the 4th quarter. Bank of Montreal Can now owns 160,474 shares of the company’s stock worth $976,000 after purchasing an additional 6,692 shares in the last quarter. 98.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SLN shares. HC Wainwright reiterated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, June 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald initiated coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating on the stock. Finally, Morgan Stanley lifted their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.50.

Silence Therapeutics Price Performance

Silence Therapeutics stock opened at $14.59 on Friday. The stock has a market cap of $878.46 million, a P/E ratio of -11.40 and a beta of 1.45. Silence Therapeutics PLC Sponsored ADR has a 1 year low of $4.19 and a 1 year high of $17.58. The firm’s 50 day moving average price is $12.06 and its 200-day moving average price is $8.43.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. As a group, equities analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.03 EPS for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.